Goldman Sachs
TNGX icon

Goldman Sachs’s Tango Therapeutics TNGX Stock Holding History

Goldman Sachs’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312M Buy
9,980,620
+4,904,228
+97% +$121M 0.03% 578
2026
Q1 		$106M Buy
5,076,392
+133,978
+3% +$1.86M 0.01% 987
2025
Q4 		$43.8M Buy
4,942,414
+3,432,939
+227% +$29.6M 0.01% 1617
2025
Q3 		$12.7M Buy
1,509,475
+1,401,296
+1,295% +$9.48M ﹤0.01% 2735
2025
Q2 		$554K Sell
108,179
-64,254
-37% -$159K ﹤0.01% 5095
2025
Q1 		$236K Sell
172,433
-314,455
-65% -$772K ﹤0.01% 5568
2024
Q4 		$1.5M Sell
486,888
-56,609
-10% -$263K ﹤0.01% 4528
2024
Q3 		$4.18M Sell
543,497
-71,421
-12% -$682K ﹤0.01% 3498
2024
Q2 		$5.28M Buy
614,918
+1,216
+0.2% +$9.4K ﹤0.01% 3101
2024
Q1 		$4.87M Buy
613,702
+164,487
+37% +$1.76M ﹤0.01% 3114
2023
Q4 		$4.45M Buy
449,215
+334,355
+291% +$2.9M ﹤0.01% 3261
2023
Q3 		$1.29M Buy
114,860
+24,293
+27% +$148K ﹤0.01% 4087
2023
Q2 		$301K Buy
90,567
+9,408
+12% +$33.8K ﹤0.01% 5003
2023
Q1 		$321K Buy
81,159
+11,125
+16% +$64.6K ﹤0.01% 5071
2022
Q4 		$508K Sell
70,034
-204,552
-74% -$1.44M ﹤0.01% 4857
2022
Q3 		$994K Buy
274,586
+194,191
+242% +$829K ﹤0.01% 4507
2022
Q2 		$364K Sell
80,395
-21,391
-21% -$130K ﹤0.01% 5301
2022
Q1 		$772K Buy
101,786
+19,180
+23% +$166K ﹤0.01% 5030
2021
Q4 		$904K Buy
+82,606
New +$993K ﹤0.01% 4932

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's TNGX Position: Q2 2026 in Review

Goldman Sachs increased its Tango Therapeutics (TNGX) stake by 97% in Q2 2026, buying an estimated $121M and bringing the position to 9,980,620 shares worth $312M. The position accounts for 0.03% of the portfolio, ranked #578.

Goldman Sachs first reported a position in TNGX in Q4 2021 and has held it in 19 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Goldman Sachs held 9,980,620 shares of Tango Therapeutics worth $312M as of Q2 2026.
  • Goldman Sachs bought 4,904,228 Tango Therapeutics shares in Q2 2026, an estimated $121M.
  • Tango Therapeutics made up 0.03% of Goldman Sachs's portfolio in Q2 2026, its #578 holding.
  • Goldman Sachs first reported a position in Tango Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.